TD Cowen has pinpointed Agios Pharmaceuticals as its preferred pick within the biotechnology sector, highlighting recent regulatory progress and strategic pipeline changes that support the recommendation.
The firm’s endorsement rests primarily on two factors: Agios’ commercial entry for thalassemia and momentum across its development pipeline. Key among the recent regulatory milestones is the FDA’s acceptance of the company’s supplemental New Drug Application for mitapivat in sickle cell disease, along with the grant of priority review. The agency has set a Prescription Drug User Fee Act date of November 1, 2026.
TD Cowen interprets the priority review designation as an indicator of regulatory alignment with mitapivat’s approvability based on the Phase 3 RISE-UP study, rather than a mere procedural step. The firm notes this outcome runs counter to more pessimistic views that had expected either a Complete Response Letter or a Refuse to File decision.
Some market skeptics had expressed doubts about mitapivat’s chances in sickle cell disease, especially after competitor Novo Nordisk reported positive vaso-occlusive crisis results for etavopivat in April. Even so, the FDA’s acceptance of the filing and the assignment of priority review - with no current signal that an Advisory Committee meeting will be required - point to a clearer regulatory path for mitapivat, according to TD Cowen.
TD Cowen also suggests the priority review may give mitapivat an advantage in timing, potentially providing additional lead time before a possible market entry by Novo Nordisk’s etavopivat. The firm argues that, if mitapivat gains early adoption, that usage could persist and be significant in what TD Cowen characterizes as a multi-billion dollar opportunity in sickle cell disease. The firm emphasizes that even a relatively small market share would be meaningful given that investor expectations for Agios appear to be near zero.
Analysts at TD Cowen further point to commercial dynamics that could support strong margins on new sickle cell sales. Any incremental revenue from that indication is expected to be highly profitable because of substantial marketing overlap with mitapivat’s already approved indications.
On the pipeline front, Agios recently secured exclusive global rights to cevidoplenib from Oscotec for immune thrombocytopenia and has stopped development of tebapivat for a blood disorder. Following these moves, H.C. Wainwright raised its price target on Agios’ stock, reflecting the updated program priorities.
Overall, TD Cowen’s call on Agios is grounded in the company’s regulatory progress for mitapivat, the potential commercial economics for additional sickle cell sales, and targeted pipeline changes. The firm portrays these developments as collectively supportive of the stock’s upside, particularly given currently muted investor expectations.